Computer-aid drug design, synthesis, and anticoagulant activity evaluation of novel dabigatran derivatives as thrombin inhibitors

Eur J Pharm Sci. 2019 Sep 1:137:104965. doi: 10.1016/j.ejps.2019.104965. Epub 2019 Jun 25.

Abstract

In this study, computer-aided drug design techniques were adopted to explore the structural and chemical features for dabigatran and design novel derivatives. The built 3D-QSAR models demonstrated significant statistical quality and excellent predictive ability by internal and external validation. Based on QSAR information, 11 novel dabigatran derivatives (12a-12k) were designed and predicted, then ADME prediction and molecular docking were performed. Furthermore, all designed compounds were synthesized and characterized by 1H NMR, 13C NMR and HR-MS. Finally, they were evaluated for anticoagulant activity in vitro. The activity results showed that the 10 obtained compounds exhibited comparable activity to the reference dabigatran (IC50 = 9.99 ± 1.48 nM), except for compound 12i. Further analysis on molecular docking was performed on three compounds (12a, 12c and 12g) with better activity (IC50 = 11.19 ± 1.70 nM, IC50 = 10.94 ± 1.85 nM and IC50 = 11.19 ± 1.70 nM). MD simulations (10 ns) were carried out, and their binding free energies were calculated, which showed strong hydrogen bond and pi-pi stacking interactions with key residues Gly219, Asp189 and Trp60D. The 10 novel dabigatran derivatives obtained can be further studied as anticoagulant candidate compounds.

Keywords: Anticoagulant activity; Computer-aided drug design; Dabigatran derivatives; Synthesis.

MeSH terms

  • Anticoagulants* / chemistry
  • Anticoagulants* / pharmacokinetics
  • Anticoagulants* / pharmacology
  • Computer-Aided Design
  • Dabigatran / analogs & derivatives*
  • Dabigatran / chemistry
  • Dabigatran / pharmacokinetics
  • Dabigatran / pharmacology
  • Drug Design
  • Molecular Docking Simulation
  • Quantitative Structure-Activity Relationship
  • Thrombin / antagonists & inhibitors

Substances

  • Anticoagulants
  • Thrombin
  • Dabigatran